Immunome inc IMNM.US 總覽分析

美股醫療保健
(IMNM 無簡報檔)

IMNM 投資分析

看多重點：

  • 價值≥4
  • 股利≥2

分析結論

價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位

IMNM 近期報酬表現

-3.95%

Immunome inc

1.99%

同產業平均

-0.64%

S&P500

與 IMNM 同產業的標的表現

  • JSPR Jasper therapeutics inc
    價值 1 分趨勢 3 分波段 4 分籌碼 3 分股利 1 分
    查看更多

IMNM 公司資訊

Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

IMNM 股價